Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Conditions:   Unresectable Colon Cancer Peritoneal Metastases;   PMMR/Ras/BRAF Wild-type Intervention:   Drug: Serplulimab Combined With FOLFIRI and Bevacizumab Sponsors:   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Changxing People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials